SCHEMBL15445880

SCHEMBL15445880

N#Cc1ccc(-c2cnc3ccccc3c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.60
PDGFRA P16234 2/20 0.60
RIPK1 Q13546 1/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
PARP1 P09874 2/20 0.55
PIK3CD O00329 2/20 0.54
PIK3CA P42336 2/20 0.54
CYP2A6 P11509 1/20 0.53
BIRC5 O15392 1/20 0.51
GABRA1 P14867 1/20 0.49
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA5 P31644 1/20 0.49
GABRA3 P34903 1/20 0.49
NISCH Q9Y2I1 1/20 0.48
PIK3CB P42338 1/20 0.47
MTOR P42345 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23204883 0.93 PDGFRB (0.53) PDGFRBPDGFRARIPK1CA12CA1
SCHEMBL23204645 0.93 PDGFRB (0.53) PDGFRBPDGFRARIPK1CA12CA1
SCHEMBL29788929 0.86 PIK3CD (0.61) PDGFRBPDGFRACA12CA1CA2
SCHEMBL11987325 0.85 PDGFRB (0.44) PDGFRBPDGFRARIPK1CA12CA1
SCHEMBL27914425 0.83 PDGFRB (0.60) PDGFRBPDGFRACA12CA1CA2
SCHEMBL29375510 0.82 PDGFRB (0.72) PDGFRBPDGFRACA12CA1CA2
SCHEMBL24621829 0.82 PDGFRB (0.72) PDGFRBPDGFRACA12CA1CA2
SCHEMBL26829682 0.82 PDGFRB (0.72) PDGFRBPDGFRACA12CA1CA2
SCHEMBL22064668 0.82 BIRC5 (0.45) PDGFRBPDGFRARIPK1CA12CA1
SCHEMBL2772360 0.82 PDGFRB (0.77) PDGFRBPDGFRACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 US disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME ODC1, AOC1, ADH1C PDGFRB 1422/4885PDGFRA 2010/4885RIPK1 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.